Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19311891 | 0.84 | HPGD (0.53) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL27553012 | 0.84 | GPR119 (0.48) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL4367475 | 0.83 | CHRM2 (0.34) | HPGDGPR119HSD11B1 | |
| SCHEMBL20310798 | 0.82 | HPGD (0.49) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL22137967 | 0.81 | HPGD (0.48) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL9964560 | 0.81 | BTK (0.37) | HPGDGPR119EPHX1HSD11B1 | |
| SCHEMBL4711418 | 0.80 | HPGD (0.55) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL27948318 | 0.80 | HPGD (0.49) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL574102 | 0.80 | BTK (0.36) | HPGDEPHX1HSD11B1 | |
| SCHEMBL19633473 | 0.79 | HPGD (0.54) | HPGDGPR119RECQLEPHX1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | HPGD 1796/4885GPR119 1/4885RECQL 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.